CureVac up 13% as court upholds validity of patent in BioNTech spat

Trump Reportedly Seeking Exclusive Access To Coronavirus Vaccine From German Biotech Firm CureVac

Matthias Hangst/Getty Images News

  • CureVac (NASDAQ:CVAC) is up ~13% in after-hours trading Thursday after the European Patent Court deemed valid a key patent that the biotech says is central to its technology amid a challenge from German rival BioNTech (NASDAQ:BNTX).
  • The patent in question, EP

Leave a Reply

Your email address will not be published. Required fields are marked *